BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression
Authors:
Open Access
- 4 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (10) , 1598-1611
Abstract
The role of Th17 cells in prostate cancer is not fully understood. The transcription factor BATF controls the differentiation of Th17 cells. Mice deficient in Batf do not produce Th17 cells. In this study, we aimed to characterize the role of Batf-dependent Th17 cells in prostate cancer by crossbreeding Batf knockout mice with mice conditionally mutant for Pten. We found that Batf knockout mice had changes in the morphology of prostate epithelial cells compared with normal mice, and Batf knockout mice deficient in Pten (called Batf-) had smaller prostate size and developed fewer invasive prostate adenocarcinomas than Pten-deficient mice with Batf expression (called Batf+). The prostate tumors in Batf- mice showed reduced proliferation, increased apoptosis, decreased angiogenesis and inflammatory cell infiltration, and activation of nuclear factor–κB signaling. Moreover, Batf- mice showed significantly reduced interleukin 23 (IL-23)-IL-23R signaling. In the prostate stroma of Batf- mice, IL-23R–positive cells were decreased considerably compared with Batf+ mice. Splenocytes and prostate tissues from Batf- mice cultured under Th17 differentiation conditions expressed reduced IL-23/IL-23R than cultured cells from Batf+ mice. Anti–IL-23p19 antibody treatment of Pten-deficient mice reduced prostate tumors and angiogenesis compared with control immunoglobulin G–treated mice. In human prostate tumors, BATF messenger RNA level was positively correlated with IL-23A and IL-23R but not RORC. Our novel findings underscore the crucial role of IL-23-IL-23R signaling in mediating the function of Batf-dependent Th17 cells, thereby promoting prostate cancer initiation and progression. This finding highlights the BATF–IL-23R axis as a promising target for the development of innovative strategies for prostate cancer prevention and treatment.Keywords
Funding Information
- National Cancer Institute
- National Institutes of Health (R01 CA255802)
- National Institute of General Medical Sciences
- National Institutes of Health (P20 GM103629)
- University Senate Committee on Research Fellowship Program Award
- Carol Lavin Bernick faculty
This publication has 27 references indexed in Scilit:
- CD4+ T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasionThe Prostate, 2020
- Targeting Th17‐IL‐17 Pathway in Prevention of Micro‐Invasive Prostate Cancer in a Mouse ModelThe Prostate, 2017
- Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transitionOncogene, 2016
- A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisDermatology and Therapy, 2015
- Interleukin‐17 promotes development of castration‐resistant prostate cancer potentially through creating an immunotolerant and pro‐angiogenic tumor microenvironmentThe Prostate, 2014
- A Validated Regulatory Network for Th17 Cell SpecificationCell, 2012
- BATF–JUN is critical for IRF4-mediated transcription in T cellsNature, 2012
- Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patientsInternational Journal of Cancer, 2009
- The AP-1 transcription factor Batf controls TH17 differentiationNature, 2009
- IL-23 promotes tumour incidence and growthNature, 2006